Summary

Asia Pacific Antidepressant Drugs Market is valued approximately USD 4.17 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.55% over the forecast period 2024-2032. Antidepressants are common prescription medications that can help treat depression and other conditions such as anxiety and obsessive-compulsive disorder. Healthcare providers prescribe them to treat other conditions such as depression and other mental condition. These drugs work by affecting the levels of certain chemicals in the brain, such as norepinephrine and serotonin. Furthermore, awareness of mental health issues is rising in many countries in Asia Pacific region, which is leading to demand for mental health services and treatments, including antidepressant medications in the Asia Pacific Antidepressant Drugs Market.


The Asia Pacific Antidepressant Drugs Market is driven by rising healthcare spending, leading to greater access to healthcare services and pharmaceuticals, including antidepressant medications. across the region. Moreover, rising prevalence of metal disorders such as Depression and other mental health disorders in the APAC region, and rising geriatric population in the region is driving demand for antidepressant medications. In addition, rising government support and rising drug approval activities in the region is creating new opportunities to the market growth. However, availability of alternative mode of treatment and limited reimbursement policy in the region is going to impede the overall demand for the market during the forecast period 2024-2032.

The key Countries considered for the Asia Pacific Antidepressant Drugs market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market in terms of revenue owing to factors such as rising prevalence of mental disorders, rising healthcare expenditure, rising drug development, research and drug approval activities across the region. Furthermore, the market in India, on the other hand, is expected to develop at the fastest rate over the forecast period 2024-2032.

Major market player included in this report are:
Mayne Pharma Group Limited
Aurobindo Pharma Ltd
Wockhardt Limited
Currax Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Limited,
Jiangsu Hengrui Pharmaceuticals Company Ltd.,
Takeda Pharmaceuticals Ltd
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:


By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others

By Depressive Disorders:
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific Antidepressant Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific Antidepressant Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Product
2.3.2. By Depressive Disorder
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific Antidepressant Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific Antidepressant Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific Antidepressant Drugs Market Size & Forecasts by Product 2022-2032
5.1. Tricyclic Antidepressants
5.2. Selective Serotonin Reuptake Inhibitors
5.3. Serotonin Norepinephrine Reuptake Inhibitors
5.4. Monoamine Oxidase Inhibitors
5.5. Serotonin Antagonist and Reuptake Inhibitors
5.6. Others
Chapter 6. Asia Pacific Antidepressant Drugs Market Size & Forecasts by Depressive Disorder 2022-2032
6.1. Major Depressive Disorder
6.2. Obsessive-Compulsive Disorder
6.3. Generalized Anxiety Disorder
6.4. Panic Disorder
6.5. Others
Chapter 7. Asia Pacific Antidepressant Drugs Market Size & Forecasts by Country 2022-2032
7.1. China Antidepressant Drugs Market
7.1.1. Product breakdown size & forecasts, 2022-2032
7.1.2. Depressive Disorder breakdown size & forecasts, 2022-2032
7.2. India Antidepressant Drugs Market
7.3. Japan Antidepressant Drugs Market
7.4. Australia Antidepressant Drugs Market
7.5. South Korea Antidepressant Drugs Market
7.6. Rest of Asia Pacific Antidepressant Drugs Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Mayne Pharma Group Limited
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Aurobindo Pharma Ltd
8.3.3. Wockhardt Limited
8.3.4. Currax Pharmaceuticals LLC
8.3.5. Sun Pharmaceutical Industries Ltd
8.3.6. Zydus Lifesciences Limited,
8.3.7. Jiangsu Hengrui Pharmaceuticals Company Ltd.,
8.3.8. Takeda Pharmaceuticals Ltd
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes